Scarica l'app Stockscreener
4.07
1.21%
-0.05
Dopo l'orario di chiusura:
4.08
0.010
+0.25%
Precedente Chiudi:
$4.12
Aprire:
$4.16
Volume 24 ore:
1.83M
Relative Volume:
1.00
Capitalizzazione di mercato:
$404.75M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-2.0333
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
-0.25%
1M Prestazione:
-30.07%
6M Prestazione:
-50.96%
1 anno Prestazione:
-60.41%
Intervallo 1D:
$3.985
$4.27
Intervallo di 1 settimana:
$3.985
$4.45
Portata 52W:
$3.985
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.07 | 405.75M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 - Morningstar
Join Class Action to Recover Losses from ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale. - Stock Titan
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY - FinancialContent
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors - GlobeNewswire
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - herald-dispatch.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Class Action Alert: Levi & Korsinsky Reminds ARS Pharmaceuticals (SPRY) Investors of October 5, 2026 Deadline - ACCESS Newswire
SPRY Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASD - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before October 5, 2026 – ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Contact Levi & Korsinsky by October 5, 2026 to Join Class Action Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026 - Barchart.com
Robbins LLP Reminds SPRY Stockholders of the Pending - GlobeNewswire
SPRY STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY) InvestorsContact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with ... - Black Hills Pioneer
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASD - The National Law Review
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026 - Barchart.com
Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Securities Class Action Lawsuit Filed Against ARS Pharmaceuticals, Inc. (SPRY)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class ActionContact SueWallSt - PR Newswire
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 - PR Newswire
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Class Action Lawsuit Filed: ARS Pharmaceuticals, Inc. (SPRY)Join by October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc.October 5, 2026 Deadline - ACCESS Newswire
October 5, 2026 Deadline Approaching: Join Class Action Against ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky - ACCESS Newswire
Kaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class Action - Barchart.com
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - TMX Newsfile
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky For Information Before October 5, 2026ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026 - NewMediaWire
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of ARS Pharmaceuticals Inc. to Contact the Firm Today! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
Recover Investment Losses: Class Action Initiated Against ARS Pharmaceuticals, Inc. (SPRY) - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026 - The Globe and Mail
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline - Morningstar
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):